Corporate Overview. April 2014 OTCQB: LCDX
|
|
- Augusta Cooper
- 6 years ago
- Views:
Transcription
1 Corporate Overview April 2014 OTCQB: LCDX
2 Company Snapshot biopsy Provides non-invasive, point-of-care cellular imaging technologies VivaScope systems can improve patient outcomes while reducing costs to the healthcare system VivaScope is a Standard of Care in Germany with the S1 guidelines VivaScope provides physicians with a powerful tool to assist in the diagnosis of skin cancers and other skin disease VivaScope has FDA 510(k) clearance and is supported by more than 350 independently sponsored studies and publications 1
3 Caliber I.D. Brand Promise The VivaScope system provides accurate diagnostic information without the need for biopsies Accurately lets physicians identify areas that need to be treated Evaluate the wound healing process and monitors therapeutic outcomes Unlike biopsies, permits unlimited repeat assessments of suspect areas Provides peace of mind and real-time knowledge so patients and caregivers can move forward with confidence 2
4 Investment Thesis VivaScope is a proprietary platform directed to multiple large markets Academic, Medical and Therapeutic Research Caliber I.D. estimates the immediate market opportunity to be $300 million Sales to drug and cosmetic industry VivaScope competitively priced against conventional technology providers such as Olympus and Nikon Skin Cancer Screening and Diagnosis Caliber I.D estimates the near-term market opportunities in diagnosis of skin cancers to be $1 billion annually Sales to Managed Care Systems, HMOs, and independent Skin Cancer Imaging centers Surgical and Therapeutic Management Long-term market opportunity will be the most significant Real-time therapeutic and surgical procedure management Reduced surgical procedure time and reoperative rates IP protection from 78 issued or pending patents worldwide Experienced management team with a successful record of commercializing advanced medical technologies 3
5 Technology VivaScope Cellular Imaging Pinhole and Detector Laser Confocal Cellular Imaging Creates layer-by-layer scans of living tissue, with a >0.2mm imaging depth Provides a microscopic view of living cells in the skin, with a 3-5 micron cellular resolution, comparable to histology Scanning Optics and Beam Splitter Horizontal Confocal Image Microscope Objective Lens Point-of-Care Diagnosis Images entire lesions instead of portions of lesions Allows physicians to quickly diagnose melanoma and other skin cancers, rashes and many common skin conditions Reduces unnecessary biopsies of non-cancerous lesions Cost-Efficient, Patient-Friendly Fast, painless procedure, allowing for accurate diagnosis in minutes rather than days No side-effects from imaging procedure Eliminates the need for a follow-up visit 4
6 Technology VivaScope Product Platform In Vivo Cellular Imager Video Dermoscopy In Vivo Cellular Imager Ex Vivo Cellular Imager Telepathology VivaScope 1500 and VivaScope 1500 Multi Laser FDA 510(k) cleared VivaCam FDA 510(k) cleared VivaScope 3000 FDA 510(k) cleared VivaScope 2500 FDA 510(k) exempt VivaNet / VivaLAN FDA Class 1 Device Robust Intellectual Property with 78 patents issued or pending Global Distribution Networks and regulatory approvals 5
7 Immediate Commercialization Strategy Academic, Medical and Therapeutic Research Opportunity to capture research sales currently going to major microscopy manufacturers Caliber I.D. s confocal imaging provides a cost-effective solution to pre-clinical research, whereby researchers may view tissue without sacrifice Leverage current customers which include some of the most highly regarded Fortune 500 companies, academic institutions and private practices Over 300 units shipped into commercial research and academic markets and 125 units placed into clinical offices worldwide Three sales representatives targeting research organizations hired in Q4 13, with first sales made in Q1 14 Caliber I.D. estimates this market opportunity to be $300 million globally 6
8 Immediate Commercialization Strategy Academic, Medical and Therapeutic Research Current customers include some of the most highly regarded Fortune 500 companies, and academic institutions Over 300 units shipped into commercial research and academic markets Cosmetic Proctor & Gamble Johnson & Johnson Shiseido L'Oréal Avon Amway Academia Rice University Texas A&M Yale Mass General 7
9 Near-Term Commercialization Strategy Skin Cancer Screening and Diagnosis Skin cancer is the most prevalent cancer in the United States 3.5 million new cases annually and a lifetime incidence rate of 20% Exceeds the combined incidence of breast, prostate, lung and colon cancers Conventionally, skin cancers are diagnosed initially by visual inspection and biopsy, an invasive and painful procedure in which tissue is surgically removed and then examined in a laboratory over the next few days. Nearly 80% of the biopsies performed are benign Biopsies can lead to complications such as infection or scarring VivaScope reduces the need to biopsy potential to reduce biopsy rates by 80%! Patients prefer a non-invasive procedure Caliber I.D. estimates this market opportunity to be $1.0 billion globally 8
10 Near-Term Commercialization Strategy Skin Cancer Screening and Diagnosis Independent skin cancer screening clinics Developing market across healthcare continuum For the first time patients will have an option and preference for an alternative to biopsy! Potential source of high margin, recurring revenue stream for Caliber I.D. Managed Care closed system HMOs May significantly improves outcomes and reduces costs Allows fast detection of cancerous lesions that appear benign Dramatically reduces the need for expensive, painful and time-consuming biopsies There are more than 1,000 managed care organizations in the U.S. that would benefit from the VivaScope system Potential cost savings of more than $1 billion annually in the U.S., not including any productivity improvements 9
11 Near-Term Commercialization Strategy Skin Cancer Screening and Diagnosis Benign Mole Basal Cell Carcinoma Melanoma Images can be interpreted by the physician at the point of patient care, and/or Images can be securely transferred to a private-network pathologist for remote diagnosis Squamous Cell Carcinoma 10
12 Longer-Term Commercialization Strategy Surgical and Therapeutic Management In therapeutic monitoring, VivaScope allows physicians to repeatedly and nondestructively examine tissue to determine the effectiveness of therapy in real time In surgery, the technology can enable surgeons to identify, differentiate and diagnose various tissue types for rapid assessment of tissue pathology, reducing procedure time and the re-operative rate per patients, significantly reducing costs and improving patient outcomes Pathology could be performed immediately locally or remotely via VivaNet telepathology network, which would serve as a source of recurring revenues Market assessment currently underway but is expected to be the largest global opportunity 11
13 Growth Strategy Caliber I.D. is a unique platform-technology company that has the ability to address multiple high growth markets in drug research and in the cancer diagnosis/treatment markets and in clinical medicine Initially Caliber I.D. is focused on the research market, followed by the clinical diagnostic/therapeutic markets and then by therapeutic and surgical management The vision is to be a viable competitor offering an alternative confocal microscopy system to the global drug, therapeutic and clinical markets Strategic goal is to install Caliber I.D. systems in every skin cancer clinic, in daily use, generating highly profitable recurring revenues for Caliber I.D. through either a direct sale or rental programs In addition, VivaNet and VivaLan image sharing and cloud storage systems will provide for additional recurring revenues Product Service and Service Contract revenues will also be generate ongoing revenues 12
14 Approaching Milestones Continue execution/rollout of Research Sales team Opening first independent Imaging Center in May 2014 Develop and support the launch of Independent Imaging Centers across the U.S. Q2 14 Complete NCI - sponsored Melanoma study H2 14 Seek partnership with a pharmaceutical company for neuropathy applications H2 14 Began the development of new compact confocal imaging device leveraging novel technology with the University of Rochester
15 Key Financial Data Equity Metrics (April 2014) Market cap: $5.45 million Shares outstanding: 8.5 million Balance Sheet (12/31/13) Current assets: $2.3 million Debt: $11.8 million (1) Revenue 12 mos. ended 12/31/13: $3.3 million 12 mos. ended 12/31/12: $2.4 million 1 Principal of $5M plus interest will convert into common stock at closing of $6 million of financing. Remaining debt matures in
16 Investment Thesis - Recap VivaScope is a proprietary platform directed to multiple large markets Academic, Medical and Therapeutic Research Immediate market opportunity of $300 million Sales to drug and cosmetic industry VivaScope competitively priced against conventional technology providers such as Olympus and Nikon Skin Cancer Screening and Diagnosis Near-Term Market Opportunities in diagnosis of skin cancers of $1 billion annually Sales to Managed Care Systems, HMOs, and independent Skin Cancer Imaging centers Surgical and Therapeutic Management Long-term market opportunity will be the most significant Real-time therapeutic and surgical procedure management Reduced surgical procedure time and reoperative rates IP protection from 78 issued or pending patents worldwide Experienced management team with a successful record of commercializing advanced medical technologies 15
17 Forward-Looking Statements This corporate overview contains statements about Caliber Imaging & Diagnostics or Caliber I.D. s future expectations, plans and prospects that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements concerning the Company s strategic goals and objectives relating to, among other things: geographic and market expansion; new product opportunities; sales and marketing initiatives; and research and development and financial projections. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks relating to: the Company s ability to successfully obtain and maintain regulatory approvals; develop and market existing and new products; maintain key intellectual property rights; manage competitive pressures; successfully execute on its plans and strategies for growth; and overcome adverse economic and market conditions, as well as those factors described in Risk Factors and elsewhere in the Company's Annual Report on Form 10-K for the year ended December 31, 2013 and any subsequent Quarterly Reports on Form 10-Q filed to date. The forward-looking statements included in this corporate overview represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause its views to change. While the Company may elect to update these forward-looking statements in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company s views as of any date subsequent to the date hereof. 16
OBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
Craig Hallum Conference Investor Presentation
Craig Hallum Conference Investor Presentation Improving cancer outcomes with groundbreaking precision in molecular testing Paul Kinnon President and CEO Sept 2015 1 Forward-Looking Statements Certain statements
Medium Term Management Plan Next 100 Transform to Grow
Medium Term Management Plan Conference in Tokyo (June 17, 2014) NIKON CORPORATION Forward-looking statements for earnings and other performance data contained herein are based on information currently
Guide to Understanding Breast Cancer
An estimated 220,000 women in the United States are diagnosed with breast cancer each year, and one in eight will be diagnosed during their lifetime. While breast cancer is a serious disease, most patients
A Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field
A Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field Introduction The field of regenerative medicine remains at the forefront of personalized medicine and healthcare
Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
Fiscal Year 2013 (FY13) Prostate Cancer Research Program (PCRP) Reference Table of Award Mechanisms and Submission Requirements
Fiscal Year 2013 (FY13) Prostate Cancer Research Program (PCRP) Reference Table of Award Mechanisms and Submission Requirements PCRP AWARD MECHANISMS WITH EMPHASIS ON RESOURCES Clinical Consortium Award
Guarantee Trust Life Insurance Company s Platinum Plan for Cancer & Heart Attack & Stroke Coverage. Helping you enjoy all the moments of your life.
Guarantee Trust Life Insurance Company s Platinum Plan for Cancer & Heart Attack & Stroke Coverage. Helping you enjoy all the moments of your life. ADH1-09 Express Payment* $7,500 We will pay you a lump-sum
Quick Facts about Breast Augmentation with IDEAL IMPLANT Saline-filled Breast Implants
Quick Facts about Breast Augmentation with IDEAL IMPLANT Saline-filled Breast Implants Important Factors Breast Augmentation Patients Should Consider October 2015 Caution: Federal law restricts this device
Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation
Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Hans S. Keirstead President, NeoStem Oncology NeoStem Presented by GTC, a conference production company 626-256-6405
How To Combine The Two Companies Into A Single Company
Announcement no. 22/2007 To OMX The Nordic Exchange, Copenhagen, and the press Vedbæk, November 27, 2007 EXIQON TO ACQUIRE ONCOTECH INC AND ENTER THE MARKET FOR CANCER MOLECULAR DIAGNOSTICS IN 2008 Summary:
What If I Have a Spot on My Lung? Do I Have Cancer? Patient Education Guide
What If I Have a Spot on My Lung? Do I Have Cancer? Patient Education Guide A M E R I C A N C O L L E G E O F C H E S T P H Y S I C I A N S Lung cancer is one of the most common cancers. About 170,000
Cervical Cancer The Importance of Cervical Screening and Vaccination
Cervical Cancer The Importance of Cervical Screening and Vaccination Cancer Cells Cancer begins in cells, the building blocks that make up tissues. Tissues make up the organs of the body. Sometimes, this
Epizyme Announces First Quarter 2014 Financial Results and Provides Corporate Update
Epizyme Announces First Quarter 2014 Financial Results and Provides Corporate Update Initiated pediatric MLL-r Phase 1b dose escalation study of DOT1L inhibitor EPZ-5676 in May 2014; three proof-of-concept
Investor Presentation NASDAQ:BLFS
Investor Presentation NASDAQ:BLFS Safe Harbor Statement This presentation contains forward-looking statements, including, but not limited to, statements concerning the company s anticipated business and
Bring Healthcare to Life. High Definition Videoconferencing Brings Quality Care to Patients. Specialized Care. Real-Time Access.
Bring Healthcare to Life. High Definition Videoconferencing Brings Quality Care to Patients Specialized Care. Real-Time Access. Quality You Can Depend on. High Definition Videoconferencing Face to Face
Excision or Open Biopsy of a Breast Lump Your Operation Explained
Excision or Open Biopsy of a Breast Lump Your Operation Explained Patient Information Introduction This leaflet tells you about the procedure known as excision or open biopsy of a breast lump. It explains
A Letter from MabVax Therapeutics President and Chief Executive Officer
A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS?
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women
The Future of Consumer Health Care
The Future of Consumer Health Care Coming Together To Lead The Consumer Health Care Industry 2 Creating a New Business Model in Consumer Health Care 3 Serve More Consumers In More Parts of the World, More
Department of Anesthesia & Perioperative Medicine 5-Year Strategic Plan FY 2012-2016. Contents
Anesthesia & Perioperative Medicine 167 Ashley Avenue, Suite 301 MSC 912 Charleston, SC 29425-9120 Tel 843 792 2322 Fax 843 792 9314 Department of Anesthesia & Perioperative Medicine 5-Year Strategic Plan
TAPPING THE POTENTIAL OF TELEHEALTH. Balaji Satyavarapu [Professional IT Consulting
] Balaji Satyavarapu [Professional IT Consulting TELEHEALTH What is it? As recently defined by the Telehealth Advancement Act of 2011 in Section 2290.5 of the California Business and Professions Code,
Early Prostate Cancer: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Early Prostate Cancer:
Loma Linda University and Siemens PETNET Solutions, Inc.
Loma Linda University and Siemens PETNET Solutions, Inc. announce operational state-of-theart PET production and research facility to advance molecular imaging FOR IMMEDIATE RELEASE CONTACT: Susan Onuma
The Diagnosis of Cancer in the Pathology Laboratory
The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens
First Warning Systems, Inc.
First Warning Systems, Inc. Breast Cancer Early Detection System US EU/UK & Russia Executive Summary September 2012 i 1. EXECUTIVE SUMMARY 1.1 FIRST WARNING SYSTEM INTRODUCTION First Warning System (FWS)
Introduction to Pathology and Diagnostic Medicine
Harvard-MIT Division of Health Sciences and Technology HST.035: Principle and Practice of Human Pathology Dr. Badizadegan Introduction to Pathology and Diagnostic Medicine Spring 2003 What is pathology?
Chapter 13. The hospital-based cancer registry
Chapter 13. The hospital-based cancer registry J.L. Young California Tumor Registry, 1812 14th Street, Suite 200, Sacramento, CA 95814, USA Introduction The purposes of a hospital-based cancer registry
One of the most important recent developments in cancer treatment has been the ability to harvest stem
BIOTECHNOLOGY A Patient-Friendly Approach to Human Cell Transplantation One of the most important recent developments in cancer treatment has been the ability to harvest stem cells from bone marrow or
TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
Workshop: La Medicina Telematica per la disabilità è una realtà: chi, dove e quando. Esperienze di teledermatologia a Modena
Workshop: La Medicina Telematica per la disabilità è una realtà: chi, dove e quando. Esperienze di teledermatologia a Modena Prof. Alberto Giannetti Direttore Istituto Dermatologia - Università degli Studi
The Role of the MDT Coordinator. Laura Throssell
The Role of the MDT Coordinator Laura Throssell NHS Cancer Plan (2000) the care of all patients with cancer should be formally reviewed by a specialist team. all patients have the benefit of the range
Detecting Cancer in Blood. Company presentation
Detecting Cancer in Blood Company presentation Safe harbor statement Forward Looking Statements This communication contains certain forward-looking statements, including, without limitation, statements
The Brain and Spine CenTer
The Br ain and Spine Center Choosing the right treatment partner is important for patients facing tumors involving the brain, spine or skull base. The Brain and Spine Center at The University of Texas
Low-dose CT Imaging. Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital
Lung Cancer Screening with Low-dose CT Imaging Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital Despite recent declines in the incidence of lung cancer related to the
exactly. The need for efficiency in developing effective new therapeutics has never been greater.
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
ThermoGenesis Corp. May 2012
ThermoGenesis Corp. May 2012 Safe Harbor Certain matters discussed in this presentation are "forward-looking statements." These forward-looking statements can generally be identified as by the context
New Advances in Cancer Treatments. March 2015
New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within
PSA Screening for Prostate Cancer Information for Care Providers
All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits
FDA Regulation of Whole Slide Imaging (WSI) Devices: Current Thoughts
FDA Regulation of Whole Slide Imaging (WSI) Devices: Current Thoughts Clinical Laboratory Improvement Advisory Committee Meeting Centers for Disease Control and Prevention February 15, 2012 Tremel A. Faison,
COLONIAL LIFE & ACCIDENT INSURANCE COMPANY 1200 Colonial Life Boulevard, P. O. Box 1365 Columbia, South Carolina 29202 (800) 325-4368
COLONIAL LIFE & ACCIDENT INSURANCE COMPANY 1200 Colonial Life Boulevard, P. O. Box 1365 Columbia, South Carolina 29202 (800) 325-4368 GROUP SPECIFIED DISEASE INSURANCE Outline of Coverage (Applicable to
Breast Cancer. Sometimes cells keep dividing and growing without normal controls, causing an abnormal growth called a tumor.
Breast Cancer Introduction Cancer of the breast is the most common form of cancer that affects women but is no longer the leading cause of cancer deaths. About 1 out of 8 women are diagnosed with breast
Having a Breast Biopsy. A Guide for Women and Their Families
Having a Breast Biopsy A Guide for Women and Their Families Fast Facts n n Most women who have a breast biopsy do not have breast cancer. About 4 out of every 5 breast biopsies are negative for cancer.
Melanoma The Skin Understanding Cancer
Melanoma A form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or
AdvantEdge Healthcare Solutions October 2010
AdvantEdge Healthcare Solutions October 2010 Overview AHS provides Billing and Practice Management services and solutions to large Physician Groups, Ambulatory Surgery Centers, and Hospitals Value proposition
Access. Action. Insight. Healthcare Analytics and Marketing Communications Consultative, Analytical, and Promotional Solutions
Cardinal Health Specialty Solutions Healthcare Analytics and Marketing Communications Consultative, Analytical, and Promotional Solutions Access Action Insight In today s increasingly competitive healthcare
CRITICAL ILLNESS INSURANCE. ExtensiA. The ideal complement to your group insurance
CRITICAL ILLNESS INSURANCE ExtensiA The ideal complement to your group insurance Peace of mind within your reach Today, progress in medicine and breakthroughs in research have significantly extended our
Brain Cancer. This reference summary will help you understand how brain tumors are diagnosed and what options are available to treat them.
Brain Cancer Introduction Brain tumors are not rare. Thousands of people are diagnosed every year with tumors of the brain and the rest of the nervous system. The diagnosis and treatment of brain tumors
Guidelines for using V-CODES (Status Codes)
1 Disclaimer This presentation is intended only for use by Tulane University faculty, staff, and students. No copy or use of this presentation should occur without the permission of Tulane University.
Novel Surgery for Inoperable Brain Tumors. A Patient Guide to NeuroBlate
Novel Surgery for Inoperable Brain Tumors A Patient Guide to NeuroBlate rose ella burkhardt brain tumor and neuro-oncology center Pioneering a Promising Surgical Treatment A brain tumor diagnosis is overwhelming
Understanding Your Surgical Options For Breast Cancer
RADIATION THERAPY SYMPTOM MANAGEMENT CANCER INFORMATION Understanding Your Surgical Options For Breast Cancer In this booklet you will learn about: Role of surgery in breast cancer diagnosis and treatment
Building Supply Chain Capabilities in the Pharmaceutical Industry Part 1: Trends impacting the supply chain
Building Supply Chain Capabilities in the Pharmaceutical Industry Part 1: Trends impacting the supply chain UPS Supply Chain Solutions SM Copyright 005 United Parcel Service of America, Inc. All Rights
Disease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? www.simpsonmillar.co.uk Telephone 0844 858 3200
GUIDE TO ASBESTOS LUNG CANCER What Is Asbestos Lung Cancer? Like tobacco smoking, exposure to asbestos can result in the development of lung cancer. Similarly, the risk of developing asbestos induced lung
An introduction to Optos
An introduction to Optos Building The Retina Company Roy Davis, CEO Christine Soden, CFO 1 Forward-Looking Statements Certain statements made in this presentation are forward-looking statements. These
STANDARD OPERATING POLICY AND PROCEDURE
STANDARD OPERATING POLICY AND PROCEDURE SUBJECT: Biospecimen Request and Release Policy Number: 500.0 Policy Date: 1/16/2009 Amendment Date: N/A Revision Date: 5-3-2010 I. INTRODUCTION AND PURPOSE The
why? 75 percent The percentage of healthy individuals over age 40 who will become critically ill at some time in the future. 3
Elite coverage can help protect your savings. USAble Life s 1 coverage helps protect your family from the financial impact that can occur as the result of a heart attack, stroke or even cancer by providing
EXPANDING YOUR HORIZONS
Glaucoma Therapy EXPANDING YOUR HORIZONS Learn how to control glaucoma with SLT therapy. SLTPATIENT EDUCATION PROGRAM Glaucoma Glaucoma is a degenerative disease that if left untreated can cause permanent
Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology. November 17, 2014
Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology November 17, 2014 Forward-looking statements Our discussions during this conference call will
Explanation of your PAP smear
Explanation of your PAP smear Approximately 5-10% of PAP smears in the United States are judged to be abnormal. Too often, the woman who receives this news worries that she already has, or will develop,
Surgery Choices. National Cancer Institute. For Women with DCIS or Breast Cancer. National Institutes of Health
National Cancer Institute Surgery Choices For Women with DCIS or Breast Cancer U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health The National Cancer Institute is grateful for our
FAQ About Prostate Cancer Treatment and SpaceOAR System
FAQ About Prostate Cancer Treatment and SpaceOAR System P. 4 Prostate Cancer Background SpaceOAR Frequently Asked Questions (FAQ) 1. What is prostate cancer? The vast majority of prostate cancers develop
OPKO Health to Acquire Bio-Reference Laboratories
OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition
Automating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se
Automating Cell Biology Annual general meeting, September 7, 2015 www.phiab.se 1 PHASE HOLOGRAPHIC IMAGING (PHI) Began as a research project at Lund University, Sweden, in 2000 Founded in 2004 Sales in
Press release Regulated information
IBA TRADING UPDATE - THIRD QUARTER 2014 Louvain-La-Neuve, Belgium, 13 November 2014 - IBA (Ion Beam Applications S.A., EURONEXT), the world s leading provider of proton therapy solutions for the treatment
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
POLICY STATEMENT. Guidelines for Refractive Surgery Advertising
POLICY STATEMENT Guidelines for Refractive Surgery Advertising A joint statement of the American Academy of Ophthalmology, the American Society of Cataract and Refractive Surgery and the International
Sientra Silicone Gel Breast Implants Quick Facts About Breast Augmentation And Reconstruction
Sientra Silicone Gel Breast Implants Quick Facts About Breast Augmentation And Reconstruction About This Brochure This brochure is intended to provide you with a high level overview of the facts about
1. What is the prostate-specific antigen (PSA) test?
1. What is the prostate-specific antigen (PSA) test? Prostate-specific antigen (PSA) is a protein produced by the cells of the prostate gland. The PSA test measures the level of PSA in the blood. The doctor
LifeProtect. Cancer Cover. For Intermediary Use Only
LifeProtect Cancer Cover For Intermediary Use Only There are few families in Ireland that have been unaffected by cancer. In fact, 1 in 3 men and 1 in 4 women in Ireland* will suffer from cancer at some
Cryosurgery in Cancer Treatment: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Cryosurgery in Cancer
COLONIAL LIFE & ACCIDENT INSURANCE COMPANY P.O. Box 1365, Columbia, South Carolina 29202 1-800-325-4368
COLONIAL LIFE & ACCIDENT INSURANCE COMPANY P.O. Box 1365, Columbia, South Carolina 29202 1-800-325-4368 SPECIFIED DISEASE COVERAGE OUTLINE OF COVERAGE (Applicable to Policy Form C1000-CA) 'THIS POLICY
An Introduction to PROSTATE CANCER
An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the
PHOTOCURE ASA BUILDING A SPECIALTY PHARMA COMPANY
PHOTOCURE ASA BUILDING A SPECIALTY PHARMA COMPANY RESULTS OF THE FIRST QUARTER 2013 25 April 2013 Kjetil Hestdal, MD, President & CEO Erik Dahl, CFO DISCLAIMER The information included in this Presentation
PSA Testing for Prostate Cancer An information sheet for men considering a PSA Test
PSA Testing for Prostate Cancer An information sheet for men considering a PSA Test What is the aim of this leaflet? Prostate cancer is a serious condition. The PSA test, which can give an early indication
Diagnosis and Treatment of Common Oral Lesions Causing Pain
Diagnosis and Treatment of Common Oral Lesions Causing Pain John D. McDowell, DDS, MS University of Colorado School of Dentistry Chair, Oral Diagnosis, Medicine and Radiology Director, Oral Medicine and
.org. Metastatic Bone Disease. Description
Metastatic Bone Disease Page ( 1 ) Cancer that begins in an organ, such as the lungs, breast, or prostate, and then spreads to bone is called metastatic bone disease (MBD). More than 1.2 million new cancer
Understanding INTRABEAM Intraoperative Radiation Therapy for Breast Cancer A patient guide
Understanding INTRABEAM Intraoperative Radiation Therapy for Breast Cancer A patient guide A diagnosis of breast cancer is never easy, but today there are more treatment options than ever before. A breast
CHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc.
Neoplasms (C00-D49) March 2014 2014 MVP Health Care, Inc. CHAPTER SPECIFIC CATEGORY CODE BLOCKS C00-C14 Malignant neoplasms of lip, oral cavity and pharynx C15-C26 Malignant neoplasms of digestive organs
BNC105 PHASE II RENAL CANCER TRIAL RESULTS
ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient
There are 2 types of clinical trials that are of interest to the. The Clinical Trials Network of the Society of Nuclear Medicine
The Clinical Trials Network of the Society of Nuclear Medicine Michael M. Graham, PhD, MD The Clinical Trials Network of the Society of Nuclear Medicine was formed to provide quality assurance of both
Brain Tumor Center. A Team Approach to Treating Brain Tumors
Brain Tumor Center A Team Approach to Treating Brain Tumors Introducing Our Brain Tumor Center Making an appointment with the Brain Tumor Center at the Center for Advanced Medicine is the important first
New/Updated Patient Information
New/Updated Patient Information Please Fill Out Completely: Date: Patient Name: Nickname: First M.I. Last Date of Birth: // Age: SSN: _/_/_ Gender: M F Email: Mailing Address: Marital Status: Single Married
Jefferies Healthcare Conference
Jefferies Healthcare Conference Marc Naughton Executive Vice President and Chief Financial Officer June 2, 2015 Safe Harbor Statement This presentation may contain forward-looking statements, including
Wireless Innovation Project
Wireless Innovation Project Winners 2009 2015 1 Seva Sanitation California Institute of Technology Seva Sanitation has engineered an intelligent system that treats black water, providing a sustainable
National Framework for Excellence in
National Framework for Excellence in Lung Cancer Screening and Continuum of Care declaration of purpose Rights and Expectations THE RIGHTS OF THE PEOPLE Lung cancer kills more Americans than the next four
POLICY STATEMENT. Guidelines for Refractive Surgery Advertising. Statement of Purpose:
POLICY STATEMENT Guidelines for Refractive Surgery Advertising Statement of Purpose: These guidelines are designed to assist ophthalmologists in providing truthful, informative advertising of refractive
COLONIAL LIFE & ACCIDENT INSURANCE COMPANY P.O. Box 1365, Columbia, South Carolina 29202 1-800-325-4368
COLONIAL LIFE & ACCIDENT INSURANCE COMPANY P.O. Box 1365, Columbia, South Carolina 29202 1-800-325-4368 SPECIFIED DISEASE COVERAGE OUTLINE OF COVERAGE (Applicable to Policy Form C1000-PA-R) THIS POLICY
NEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER
Media Release April 7, 2009 For Immediate Release NEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER London, Ontario Improved hybrid imaging techniques developed
Breast Implants: Local Complications and Adverse Outcomes
Breast Implants: Local Complications and Adverse Outcomes This booklet highlights the most common problems associated with silicone gel-filled and saline-filled breast implants: those that occur in the
2019 Healthcare That Works for All
2019 Healthcare That Works for All This paper is one of a series describing what a decade of successful change in healthcare could look like in 2019. Each paper focuses on one aspect of healthcare. To
Cancer of the Cervix
Cancer of the Cervix WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500 A woman's cervix (the opening of the uterus) is lined with cells. Cancer of the cervix occurs when those cells change,
Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
Management Discussion and Analysis
Management Discussion and Analysis MARKET REVIEW The economy for China continued to grow robustly with GDP growth of 9.6 percent in 2004. The austerity measures implemented by the Chinese government have
SOLUTIONS Cancer supplemental cancer insurance
Available for state of Arkansas employees. WASHINGTON NATIONAL SOLUTIONS Cancer supplemental cancer insurance Benefits. Options. Advocacy. CN-BR-C-SOA PLAN C Each year, millions of Americans are diagnosed
METASTASES TO THE BONE
RADIATION THERAPY FOR METASTASES TO THE BONE Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY WHAT ARE BONE METASTASES? Cancer that starts
Thymus Cancer. This reference summary will help you better understand what thymus cancer is and what treatment options are available.
Thymus Cancer Introduction Thymus cancer is a rare cancer. It starts in the small organ that lies in the upper chest under the breastbone. The thymus makes white blood cells that protect the body against
Skin cancer Patient information
Skin cancer Patient information What is cancer? The human body is made up of billions of cells. In healthy people, cells grow, divide and die. New cells constantly replace old ones in an orderly way. This
LUNG CANCER SCREENING: UNDERSTANDING LUNG NODULES. 1-800-298-2436 LungCancerAlliance.org
LUNG CANCER SCREENING: UNDERSTANDING LUNG NODULES 1-800-298-2436 LungCancerAlliance.org 1 1 CONTENTS What is a Nodule?...3 Finding Nodules...4 If a Nodule Is Found...5 What Happens Next?...7 Questions
INFORMED CONSENT FOR SLEEVE GASTRECTOMY
INFORMED CONSENT FOR SLEEVE GASTRECTOMY This informed-consent document has been prepared to help inform you about your Sleeve Gastrectomy including the risks and benefits, as well as alternative treatments.